المؤلفون: Phan, Giao Q., Yang, James C., Sherry, Richard M., Hwu, Patrick, Topalian, Suzanne L., Schwartzentruber, Douglas J., Restifo, Nicholas P., Haworth, Leah R., Seipp, Claudia A., Freezer, Linda J., Morton, Kathleen E., Mavroukakis, Sharon A., Duray, Paul H., Steinberg, Seth M., Allison, James P., Davis, Thomas A., Rosenberg, Steven A.

المصدر: Proceedings of the National Academy of Sciences of the United States of America, 2003 Jul 01. 100(14), 8372-8377.

الوصول الحر: https://www.jstor.org/stable/3139934Test

المؤلفون: Park, Tristen S., Phan, Giao Q., Yang, James C., Kammula, Udai, Hughes, Marybeth S., Trebska-McGowan, Kasia, Morton, Kathleen E., White, Donald E., Rosenberg, Steven A., Sherry, Richard M.

المصدر: Annals of Surgical Oncology ; volume 24, issue 4, page 947-951 ; ISSN 1068-9265 1534-4681

مصطلحات موضوعية: Oncology, Surgery

الإتاحة: https://doi.org/10.1245/s10434-017-5768-8Test

المؤلفون: Kochenderfer, James N., Somerville, Robert P.T., Lu, Tangying, Yang, James C., Sherry, Richard M., Feldman, Steven A., McIntyre, Lori, Bot, Adrian, Rossi, John, Lam, Norris, Rosenberg, Steven A.

المساهمون: NIH National Cancer Institute Center for Cancer Research, Kite Pharma, Inc., NCI Surgery Branch

المصدر: Molecular Therapy ; volume 25, issue 10, page 2245-2253 ; ISSN 1525-0016

الإتاحة: https://doi.org/10.1016/j.ymthe.2017.07.004Test
https://api.elsevier.com/content/article/PII:S1525001617303180?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1525001617303180?httpAccept=text/plainTest

المؤلفون: Klemen, Nicholas D., Feingold, Paul L., Goff, Stephanie L., Hughes, Marybeth S., Kammula, Udai S., Yang, James C., Schrump, David S., Rosenberg, Steven A., Sherry, Richard M.

المصدر: Annals of Surgical Oncology ; volume 24, issue 1, page 135-141 ; ISSN 1068-9265 1534-4681

مصطلحات موضوعية: Oncology, Surgery

الإتاحة: https://doi.org/10.1245/s10434-016-5537-0Test

المؤلفون: Morgan, Richard A., Dudley, Mark E., Wunderlich, John R., Hughes, Marybeth S., Yang, James C., Sherry, Richard M., Royal, Richard E., Topalian, Suzanne L., Kammula, Udai S., Restifo, Nicholas P., Zheng, Zhili, Nahvi, Azam, de Vries, Christiaan R., Rogers-Freezer, Linda J., Mavroukakis, Sharon A., Rosenberg, Steven A.

المصدر: Science, 2006 Oct 01. 314(5796), 126-129.

الوصول الحر: https://www.jstor.org/stable/20031484Test

المؤلفون: Yang, James C., Sherry, Richard M.

المصدر: Nature Reviews Clinical Oncology ; volume 11, issue 11, page 680-680 ; ISSN 1759-4774 1759-4782

مصطلحات موضوعية: Oncology

الإتاحة: https://doi.org/10.1038/nrclinonc.2014.65-c2Test
http://www.nature.com/articles/nrclinonc.2014.65-c2Test
http://www.nature.com/articles/nrclinonc.2014.65-c2.pdfTest

المؤلفون: Parkhurst, Maria R, Yang, James C, Langan, Russell C, Dudley, Mark E, Nathan, Debbie-Ann N, Feldman, Steven A, Davis, Jeremy L, Morgan, Richard A, Merino, Maria J, Sherry, Richard M, Hughes, Marybeth S, Kammula, Udai S, Phan, Giao Q, Lim, Ramona M, Wank, Stephen A, Restifo, Nicholas P, Robbins, Paul F, Laurencot, Carolyn M, Rosenberg, Steven A

المصدر: Molecular Therapy ; volume 19, issue 3, page 620-626 ; ISSN 1525-0016

الإتاحة: https://doi.org/10.1038/mt.2010.272Test
https://api.elsevier.com/content/article/PII:S1525001616304117?httpAccept=text/plainTest
https://api.elsevier.com/content/article/PII:S1525001616304117?httpAccept=text/xmlTest

المؤلفون: Palmore, Tara N., Shea, Yvonne R., Childs, Richard W., Sherry, Richard M., Walsh, Thomas J.

المصدر: Journal of Clinical Microbiology ; volume 48, issue 1, page 338-342 ; ISSN 0095-1137 1098-660X

الوصف: After allogeneic stem cell transplantation, a 49-year-old man developed fever and inflammation at the site of a plant puncture on a finger. A hyalohyphomycete was recovered by incubating the plant spine fragment following surgery. Amplification of the internal transcribed spacer region and 5.8S rRNA, β-tubulin, and translation elongation factor coding genes identified Fusarium proliferatum , which was confirmed later by culture.

الإتاحة: https://doi.org/10.1128/jcm.01525-09Test

المؤلفون: Klapper, Jacob A., Downey, Stephanie G., Smith, Franz O., Yang, James C., Hughes, Marybeth S., Kammula, Udai S., Sherry, Richard M., Royal, Richard E., Steinberg, Seth M., Rosenberg, Steven

المصدر: Cancer ; volume 113, issue 2, page 293-301 ; ISSN 0008-543X 1097-0142

الوصف: BACKGROUND. The treatment of metastatic renal cell carcinoma (RCC) with high‐dose interleukin‐2 (HD IL‐2) has resulted in durable tumor regression in a minority of patients. The current study presents the authors' 20‐year experience administering this immunotherapeutic agent. METHODS. Patients with metastatic RCC (n = 259) were treated with HD IL‐2 alone from January 13, 1986 through December 31, 2006 at the Surgery Branch of the National Cancer Institute. Potential predictive factors for response and survival, both pretreatment and treatment‐related, were first subjected to univariate analysis and then to multivariate logistic regression or a Cox proportional hazards model. Finally, the authors investigated Memorial Sloan‐Kettering Cancer Center (MSKCC) prognostic factors for survival to assess their predictive value in the patient population in the current study. RESULTS. A total of 23 patients experienced a complete response and 30 patients achieved a partial response, for an overall objective response rate of 20%. All partial responders had developed disease recurrence at the time of last follow‒up, but only 4 complete responders had experienced disease recurrence by that time. Despite toxicities, only 2 patients developed treatment‐related mortalities over this same time period. A higher baseline weight ( P = .05) and MSKCC prognostic factors ( P = .02) were found to be the variables most associated with response. For survival >4 years and overall survival, several pretreatment and treatment‒related factors maintained significance, but none more so than response ( P < .0001). CONCLUSIONS. HD IL‐2 can induce complete tumor regression in a small number of patients, and many patients have experienced extended disease‐free intervals. Given its relative safety, HD IL‐2 should still be considered a first‐line therapy in patients with metastatic RCC who have an overall good performance status. Cancer 2008. Published 2008 American Cancer Society.

الإتاحة: https://doi.org/10.1002/cncr.23552Test

المؤلفون: Illouz, Frédéric, Wang, Daniel Y, Ye, Fei, Zhao, Shilin, Johnson, Douglas B, Gupta, A., De Felice, K. M., Loftus, E. V., Khanna, S., Beck, Kimberly E., Blansfield, Joseph A., Tran, Khoi Q., Feldman, Andrew L., Hughes, Marybeth S., Royal, Richard E., Kammula, Udai S., Topalian, Suzanne L., Sherry, Richard M., Kleiner, David, Quezado, Martha, Lowy, Israel, Yellin, Michael, Rosenberg, Steven A., Yang, James C., Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, Franck, Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., Massard, C., Fuerea, A., Ribrag, V., Gazzah, A., Armand, J. P., Amellal, N., Angevin, E., Noel, N., Boutros, C., Mateus, C., Robert, C., Soria, J. C., Marabelle, A., Lambotte, O., Gonzalez, Raul S., Salaria, Safia N., Bohannon, Caitlin D., Huber, Aaron R., Feely, Michael M., Shi, Chanjuan, Marthey, L., Mussini, C., Nachury, M., Nancey, S., Grange, F., Zallot, C., Peyrin-Biroulet, L., Rahier, J. F., de Beauregard, M. Bourdier, Mortier, L., Coutzac, C., Soularue, E., Lanoy, E., Kapel, N., Planchard, D., Chaput, N., Benson, Al B., Ajani, Jaffer A., Catalano, Robert B., Engelking, Constance, Kornblau, Steven M., Martenson, James A., McCallum, Richard, Mitchell, Edith P., O'Dorisio, Thomas M., Vokes, Everett E., Wadler, Scott, Haanen, J B A G, Kerr, K M, Peters, S, Larkin, J, Jordan, K, Bergqvist, Viktoria, Hertervig, Erik, Gedeon, Peter, Kopljar, Marija, Griph, Håkan, Kinhult, Sara, Carneiro, Ana, Marsal, Jan, Hsieh, Amy Hsin Chieh, Ferman, Mutaz, Brown, Michael P., Andrews, Jane M., Trainer, Harris, Hulse, Paul, Higham, Claire E, Trainer, Peter, Lorigan, Paul, Hughes, Jing, Vudattu, Nalini, Sznol, Mario, Gettinger, Scott, Kluger, Harriet, Lupsa, Beatrice, Herold, Kevan C

المصدر: Illouz , F , Wang , D Y , Ye , F , Zhao , S , Johnson , D B , Gupta , A , De Felice , K M , Loftus , E V , Khanna , S , Beck , K E , Blansfield , J A , Tran , K Q , Feldman , A L , Hughes , M S , Royal , R E , Kammula , U S , Topalian , S L , Sherry , R M , Kleiner , D , Quezado , M , Lowy , I , Yellin ....

مصطلحات موضوعية: 80 and over, Adult, Aged, Anti-CTLA-4, Anti-PD-1 antibody, Antibodies, Antigens, Autoimmune, Autoimmune Diseases, Autoimmunity, CD, CTLA-4 Antigen, Colitis, Cytotoxic, Cytotoxic T-lymphocyte-associated antigen 4, Dermatitis, Diabetes Mellitus, Differentiation, Disease Progression, Enterocolitis, Female, HLA-A2 Antigen, Hepatitis, Humans, Immune Tolerance, Immune checkpoint blockade, Immune-checkpoint inhibitor induced enterocolitis, Immune-related adverse events, Immunotherapy, Injections

الوصف: PURPOSE: Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) is an inhibitory receptor on T cells. Knocking out CTLA4 in mice causes lethal lymphoproliferation, and polymorphisms in human CTLA4 are associated with autoimmune disease. Trials of the anti-CTLA4 antibody ipilimumab (MDX-010) have resulted in durable cancer regression and immune-mediated toxicities. A report on the diagnosis, pathology, treatment, clinical outcome, and significance of the immune-mediated enterocolitis seen with ipilimumab is presented. PATIENTS AND METHODS: We treated 198 patients with metastatic melanoma (MM) or renal cell carcinoma (RCC) with ipilimumab. RESULTS: The overall objective tumor response rate was 14%. We observed several immune mediated toxicities including dermatitis, enterocolitis, hypophysitis, uveitis, hepatitis, and nephritis. Enterocolitis, defined by grade 3/4 clinical presentation and/or biopsy documentation, was the most common major toxicity (21% of patients). It presented with diarrhea, and biopsies showed both neutrophilic and lymphocytic inflammation. Most patients who developed enterocolitis responded to high-dose systemic corticosteroids. There was no evidence that steroid administration affected tumor responses. Five patients developed perforation or required colectomy. Four other patients with steroid-refractory enterocolitis appeared to respond promptly to tumor necrosis factor alpha blockade with infliximab. Objective tumor response rates in patients with enterocolitis were 36% for MM and 35% for RCC, compared with 11% and 2% in patients without enterocolitis, respectively (P = .0065 for MM and P = .0016 for RCC). CONCLUSION: CTLA4 seems to be a significant component of tolerance to tumor and in protection against immune mediated enterocolitis and these phenomena are significantly associated in cancer patients.

الإتاحة: https://doi.org/10.1200/JCO.2005.04.5716Test
https://doi.org/10.1093/annonc/mdx225Test
https://research.manchester.ac.uk/en/publications/c96492ba-f502-4153-9d45-ee97a4c60cceTest
http://www.mendeley.com/research/enterocolitis-patients-cancer-after-antibody-blockade-cytotoxic-tlymphocyteassociated-antigen-4-2Test